Prior cervical cytology and high-risk HPV testing results for 311 patients with invasive cervical adenocarcinoma: a multicenter retrospective study from China’s largest independent operator of pathology laboratories
Abstract Background High-risk human papillomavirus (HR-HPV) testing is more sensitive than cytology for the detection of cervical cancer and its precursors. However, limited and inconsistent data are available about the efficacy of the combination of these two methods for screening cervical adenocar...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-11-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12879-019-4614-y |
| _version_ | 1818530381868040192 |
|---|---|
| author | Fengxiang Xie Liran Zhang Dongman Zhao Xuefen Wu Mingsong Wei Xuelian Zhang Xiaohui Wu Hao Fang Xue Xu Meng Yang Debo Qi |
| author_facet | Fengxiang Xie Liran Zhang Dongman Zhao Xuefen Wu Mingsong Wei Xuelian Zhang Xiaohui Wu Hao Fang Xue Xu Meng Yang Debo Qi |
| author_sort | Fengxiang Xie |
| collection | DOAJ |
| description | Abstract Background High-risk human papillomavirus (HR-HPV) testing is more sensitive than cytology for the detection of cervical cancer and its precursors. However, limited and inconsistent data are available about the efficacy of the combination of these two methods for screening cervical adenocarcinoma. This multicenter retrospective study investigated the screening results of a cohort of Chinese patients who were subsequently diagnosed with invasive cervical adenocarcinoma, with the goal of identifying the optimal cervical adenocarcinoma screening method. Methods We retrospectively retrieved and analyzed the data from patients with histologically confirmed primary invasive cervical adenocarcinoma from eight local pathology laboratories operated by KingMed Diagnostics, the largest independent operator of pathology laboratories in China, over a 2-year period. Only patients who underwent cytology and/or HR-HPV testing within 6 months before the adenocarcinoma diagnosis were included. HR-HPV DNA was detected using one of two HPV test kits: the Hybrid Capture 2 (HC2) assay (Qiagen, Hilden, Germany) and an HPV genotyping panel (Yaneng Bio, Shenzhen, China). Results Of the 311 patients, 136 underwent cytology alone, 106 underwent HR-HPV testing alone, and 69 underwent cytology and HR-HPV co-testing. The sensitivities of cytology alone (64.0, 95% confidence interval [CI]: 55.9–72.0) and HR-HPV testing alone (66.0, 95% CI: 57.0–75.1) were similar (P = 0.738). The sensitivity of cytology and HR-HPV co-testing (87.0, 95% CI: 79.0–94.9) was significantly higher than that of either cytology (P = 0.001) or HR-HPV testing alone (P = 0.002). Conclusions Both cytology alone and HR-HPV testing alone showed poor screening efficiency, whereas the combination of the two clearly increased the efficiency of primary cervical adenocarcinoma screening. Thus, cytology and HR-HPV co-testing might be the most efficient cervical adenocarcinoma screening method. |
| first_indexed | 2024-12-11T17:18:58Z |
| format | Article |
| id | doaj.art-57eff98a422840839dc98c183d17f374 |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-12-11T17:18:58Z |
| publishDate | 2019-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-57eff98a422840839dc98c183d17f3742022-12-22T00:57:13ZengBMCBMC Infectious Diseases1471-23342019-11-011911810.1186/s12879-019-4614-yPrior cervical cytology and high-risk HPV testing results for 311 patients with invasive cervical adenocarcinoma: a multicenter retrospective study from China’s largest independent operator of pathology laboratoriesFengxiang Xie0Liran Zhang1Dongman Zhao2Xuefen Wu3Mingsong Wei4Xuelian Zhang5Xiaohui Wu6Hao Fang7Xue Xu8Meng Yang9Debo Qi10Department of Pathology, Jinan KingMed DiagnosticsDepartment of Pathology, Jinan KingMed DiagnosticsDepartment of Pathology, Jinan KingMed DiagnosticsDepartment of Pathology, Kunming KingMed DiagnosticsDepartment of Pathology, Guangxi KingMed DiagnosticsDepartment of Pathology, Nanjing KingMed DiagnosticsDepartment of Pathology, Chongqing KingMed DiagnosticsDepartment of Pathology, Changsha KingMed DiagnosticsDepartment of Pathology, Hefei KingMed DiagnosticsDepartment of Pathology, Zhengzhou KingMed DiagnosticsDepartment of Genetics, Jinan KingMed DiagnosticsAbstract Background High-risk human papillomavirus (HR-HPV) testing is more sensitive than cytology for the detection of cervical cancer and its precursors. However, limited and inconsistent data are available about the efficacy of the combination of these two methods for screening cervical adenocarcinoma. This multicenter retrospective study investigated the screening results of a cohort of Chinese patients who were subsequently diagnosed with invasive cervical adenocarcinoma, with the goal of identifying the optimal cervical adenocarcinoma screening method. Methods We retrospectively retrieved and analyzed the data from patients with histologically confirmed primary invasive cervical adenocarcinoma from eight local pathology laboratories operated by KingMed Diagnostics, the largest independent operator of pathology laboratories in China, over a 2-year period. Only patients who underwent cytology and/or HR-HPV testing within 6 months before the adenocarcinoma diagnosis were included. HR-HPV DNA was detected using one of two HPV test kits: the Hybrid Capture 2 (HC2) assay (Qiagen, Hilden, Germany) and an HPV genotyping panel (Yaneng Bio, Shenzhen, China). Results Of the 311 patients, 136 underwent cytology alone, 106 underwent HR-HPV testing alone, and 69 underwent cytology and HR-HPV co-testing. The sensitivities of cytology alone (64.0, 95% confidence interval [CI]: 55.9–72.0) and HR-HPV testing alone (66.0, 95% CI: 57.0–75.1) were similar (P = 0.738). The sensitivity of cytology and HR-HPV co-testing (87.0, 95% CI: 79.0–94.9) was significantly higher than that of either cytology (P = 0.001) or HR-HPV testing alone (P = 0.002). Conclusions Both cytology alone and HR-HPV testing alone showed poor screening efficiency, whereas the combination of the two clearly increased the efficiency of primary cervical adenocarcinoma screening. Thus, cytology and HR-HPV co-testing might be the most efficient cervical adenocarcinoma screening method.http://link.springer.com/article/10.1186/s12879-019-4614-yCervical adenocarcinomaCytologyHigh-risk human papillomavirus (HR-HPV) testingCo-testingCervical cancer screening |
| spellingShingle | Fengxiang Xie Liran Zhang Dongman Zhao Xuefen Wu Mingsong Wei Xuelian Zhang Xiaohui Wu Hao Fang Xue Xu Meng Yang Debo Qi Prior cervical cytology and high-risk HPV testing results for 311 patients with invasive cervical adenocarcinoma: a multicenter retrospective study from China’s largest independent operator of pathology laboratories BMC Infectious Diseases Cervical adenocarcinoma Cytology High-risk human papillomavirus (HR-HPV) testing Co-testing Cervical cancer screening |
| title | Prior cervical cytology and high-risk HPV testing results for 311 patients with invasive cervical adenocarcinoma: a multicenter retrospective study from China’s largest independent operator of pathology laboratories |
| title_full | Prior cervical cytology and high-risk HPV testing results for 311 patients with invasive cervical adenocarcinoma: a multicenter retrospective study from China’s largest independent operator of pathology laboratories |
| title_fullStr | Prior cervical cytology and high-risk HPV testing results for 311 patients with invasive cervical adenocarcinoma: a multicenter retrospective study from China’s largest independent operator of pathology laboratories |
| title_full_unstemmed | Prior cervical cytology and high-risk HPV testing results for 311 patients with invasive cervical adenocarcinoma: a multicenter retrospective study from China’s largest independent operator of pathology laboratories |
| title_short | Prior cervical cytology and high-risk HPV testing results for 311 patients with invasive cervical adenocarcinoma: a multicenter retrospective study from China’s largest independent operator of pathology laboratories |
| title_sort | prior cervical cytology and high risk hpv testing results for 311 patients with invasive cervical adenocarcinoma a multicenter retrospective study from china s largest independent operator of pathology laboratories |
| topic | Cervical adenocarcinoma Cytology High-risk human papillomavirus (HR-HPV) testing Co-testing Cervical cancer screening |
| url | http://link.springer.com/article/10.1186/s12879-019-4614-y |
| work_keys_str_mv | AT fengxiangxie priorcervicalcytologyandhighriskhpvtestingresultsfor311patientswithinvasivecervicaladenocarcinomaamulticenterretrospectivestudyfromchinaslargestindependentoperatorofpathologylaboratories AT liranzhang priorcervicalcytologyandhighriskhpvtestingresultsfor311patientswithinvasivecervicaladenocarcinomaamulticenterretrospectivestudyfromchinaslargestindependentoperatorofpathologylaboratories AT dongmanzhao priorcervicalcytologyandhighriskhpvtestingresultsfor311patientswithinvasivecervicaladenocarcinomaamulticenterretrospectivestudyfromchinaslargestindependentoperatorofpathologylaboratories AT xuefenwu priorcervicalcytologyandhighriskhpvtestingresultsfor311patientswithinvasivecervicaladenocarcinomaamulticenterretrospectivestudyfromchinaslargestindependentoperatorofpathologylaboratories AT mingsongwei priorcervicalcytologyandhighriskhpvtestingresultsfor311patientswithinvasivecervicaladenocarcinomaamulticenterretrospectivestudyfromchinaslargestindependentoperatorofpathologylaboratories AT xuelianzhang priorcervicalcytologyandhighriskhpvtestingresultsfor311patientswithinvasivecervicaladenocarcinomaamulticenterretrospectivestudyfromchinaslargestindependentoperatorofpathologylaboratories AT xiaohuiwu priorcervicalcytologyandhighriskhpvtestingresultsfor311patientswithinvasivecervicaladenocarcinomaamulticenterretrospectivestudyfromchinaslargestindependentoperatorofpathologylaboratories AT haofang priorcervicalcytologyandhighriskhpvtestingresultsfor311patientswithinvasivecervicaladenocarcinomaamulticenterretrospectivestudyfromchinaslargestindependentoperatorofpathologylaboratories AT xuexu priorcervicalcytologyandhighriskhpvtestingresultsfor311patientswithinvasivecervicaladenocarcinomaamulticenterretrospectivestudyfromchinaslargestindependentoperatorofpathologylaboratories AT mengyang priorcervicalcytologyandhighriskhpvtestingresultsfor311patientswithinvasivecervicaladenocarcinomaamulticenterretrospectivestudyfromchinaslargestindependentoperatorofpathologylaboratories AT deboqi priorcervicalcytologyandhighriskhpvtestingresultsfor311patientswithinvasivecervicaladenocarcinomaamulticenterretrospectivestudyfromchinaslargestindependentoperatorofpathologylaboratories |